The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herremans, T. M. P. T.
Right arrow Articles by Koopmans, M. P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herremans, T. M. P. T.
Right arrow Articles by Koopmans, M. P. G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Polio and Post-Polio Syndrome
The Journal of Immunology, 1999, 162: 5011-5018.
Copyright © 1999 by The American Association of Immunologists

Induction of Mucosal Immunity by Inactivated Poliovirus Vaccine Is Dependent on Previous Mucosal Contact with Live Virus1

Tineke M. P. T. Herremans2, Johan H. J. Reimerink, Annemarie M. Buisman, Tjeerd G. Kimman and Marion P. G. Koopmans

Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands

The inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis in The Netherlands. It is not clear, however, whether IPV vaccination can lead to priming of the mucosal immune system and the induction of IgA. It has been demonstrated that IPV vaccination is able to induce strong memory IgA responses in the serum of persons who have been naturally exposed to wild-type poliovirus. This has led to the hypothesis that IPV vaccination is able to induce poliovirus-specific IgA at mucosal sites in persons who have been previously primed with live poliovirus at mucosal sites. To test this hypothesis, the kinetics of the IgA response in serum and saliva after IPV vaccination were examined in persons previously vaccinated with oral poliovirus vaccine (OPV) or IPV. ELISA and enzyme-linked immunospot assays were used for the detection of poliovirus-specific IgA responses. In addition, B cell populations were separated on the basis of the expression of mucosal ({alpha}4ß7 integrin) and peripheral homing receptors (L-selectin). Parenteral IPV vaccination was able to boost systemic and mucosal IgA responses in previously OPV-vaccinated persons only. None of the previously vaccinated IPV recipients responded with the production of IgA in saliva. In agreement with this finding, a large percentage of the poliovirus-specific IgA-producing lymphocytes detected in previous OPV recipients expressed the {alpha}4ß7 integrin. It is concluded that IPV vaccination alone is insufficient to induce a mucosal IgA response against poliovirus. In mucosally (OPV-) primed individuals, however, booster vaccination with IPV leads to a strong mucosal IgA response.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
I. M. Belyakov and J. D. Ahlers
What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?
J. Immunol., December 1, 2009; 183(11): 6883 - 6892.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
B. D. Forrest, M. W. Pride, A. J. Dunning, M. R. Z. Capeding, T. Chotpitayasunondh, J. S. Tam, R. Rappaport, J. H. Eldridge, and W. C. Gruber
Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children
Clin. Vaccine Immunol., July 1, 2008; 15(7): 1042 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
T. N. McNeilly, S. W. Naylor, A. Mahajan, M. C. Mitchell, S. McAteer, D. Deane, D. G. E. Smith, J. C. Low, D. L. Gally, and J. F. Huntley
Escherichia coli O157:H7 Colonization in Cattle following Systemic and Mucosal Immunization with Purified H7 Flagellin
Infect. Immun., June 1, 2008; 76(6): 2594 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. M. Taylor, M. E. Ziman, J. Fong, J. V. Solnick, and M. Vajdy
Possible Correlates of Long-Term Protection against Helicobacter pylori following Systemic or Combinations of Mucosal and Systemic Immunizations
Infect. Immun., July 1, 2007; 75(7): 3462 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. T. M. Leung, W. W. C. van Maren, F. K. L. Chan, W. S. Chan, A. W. I. Lo, C. H. Ma, F. C. H. Tam, K. F. To, P. K. S. Chan, J. J. Y. Sung, et al.
Extremely Low Exposure of a Community to Severe Acute Respiratory Syndrome Coronavirus: False Seropositivity due to Use of Bacterially Derived Antigens.
J. Virol., September 1, 2006; 80(18): 8920 - 8928.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. Peng, L. R. Wang, V. R. Gomez-Roman, A. Davis-Warren, D. C. Montefiori, V. S. Kalyanaraman, D. Venzon, J. Zhao, E. Kan, T. J. Rowell, et al.
Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies
J. Virol., August 15, 2005; 79(16): 10200 - 10209.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
C. L. Moe, A. Sair, L. Lindesmith, M. K. Estes, and L.-A. Jaykus
Diagnosis of Norwalk Virus Infection by Indirect Enzyme Immunoassay Detection of Salivary Antibodies to Recombinant Norwalk Virus Antigen
Clin. Vaccine Immunol., November 1, 2004; 11(6): 1028 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. Arnold, D. Bumann, M. Felies, B. Gewecke, M. Sorensen, J. E. Gessner, J. Freihorst, B. U. von Specht, and U. Baumann
Enhanced Immunogenicity in the Murine Airway Mucosa with an Attenuated Salmonella Live Vaccine Expressing OprF-OprI from Pseudomonas aeruginosa
Infect. Immun., November 1, 2004; 72(11): 6546 - 6553.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
B. S. McKenzie, A. J. Corbett, S. Johnson, J. L. Brady, J. Pleasance, D. R. Kramer, J. S. Boyle, D. C. Jackson, R. A. Strugnell, and A. M. Lew
Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses
Int. Immunol., November 1, 2004; 16(11): 1613 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
C. Krieg, R. Maier, and A. Meyerhans
Gut-homing ({alpha}4{beta}7+) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors
J. Gen. Virol., June 1, 2004; 85(6): 1571 - 1579.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. R. Youngman, M. A. Franco23, N. A. Kuklin, L. S. Rott, E. C. Butcher, and H. B. Greenberg
Correlation of Tissue Distribution, Developmental Phenotype, and Intestinal Homing Receptor Expression of Antigen-Specific B Cells During the Murine Anti-Rotavirus Immune Response
J. Immunol., March 1, 2002; 168(5): 2173 - 2181.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. T. Shata and D. M. Hone
Vaccination with a Shigella DNA Vaccine Vector Induces Antigen-Specific CD8+ T Cells and Antiviral Protective Immunity
J. Virol., October 15, 2001; 75(20): 9665 - 9670.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
T. Herremans, J. H. J. Reimerink, T. G. Kimman, H. G. A. M. van der Avoort, and M. P. G. Koopmans
Antibody Responses to Antigenic Sites 1 and 3 of Serotype 3 Poliovirus after Vaccination with Oral Live Attenuated or Inactivated Poliovirus Vaccine and after Natural Exposure
Clin. Vaccine Immunol., January 1, 2000; 7(1): 40 - 44.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.